Saturday 17 October 2026
Export CMMB’s income statement to Excel — free account
Chemomab Therapeutics Ltd. Sponsored ADR
CMMB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 25.0% and free cash flow grew 47.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.27
0.02
−1.55%
Follow CMMB
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) P/E ratio
Chemomab Therapeutics Ltd. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.4× (July 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 3.4×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| TOVX Theriva Biologics, Inc. compare | 0.1× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)